Literature DB >> 9678301

Levels of soluble Fas ligand in myocarditis.

T Toyozaki1, M Hiroe, M Tanaka, S Nagata, H Ohwada, F Marumo.   

Abstract

Serum levels of soluble Fas ligand (sFasL) increased with the severity of congestive heart failure (p <0.01), and the percentages of apoptotic myocytes detected by in situ DNA nick-end labeling were significantly higher in the patients with increased levels of sFasL than in those with normal levels of sFasL (p <0.05). These findings indicated that sFasL may play an important role in pathogenesis of myocarditis.

Entities:  

Mesh：

Substances：

Year:  1998        PMID： 9678301     DOI： 10.1016/s0002-9149(98)00300-2

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN： 0002-9149            Impact factor:   2.778


  11 in total

Review 1.  Nitric oxide, cell death, and heart failure.

Authors:  Jun-ichi Oyama; Stefan Frantz; Charles Blais; Ralph A Kelly; Todd Bourcier
Journal:  Heart Fail Rev       Date:  2002-10       Impact factor: 4.214

2.  Serum levels of soluble Fas ligand in patients with silicosis.

Authors:  A Tomokuni; T Otsuki; Y Isozaki; S Kita; H Ueki; M Kusaka; T Kishimoto; A Ueki
Journal:  Clin Exp Immunol       Date:  1999-12       Impact factor: 4.330

3.  Lymphocyte Apoptosis and FAS Expression in Patients with 22q11.2 Deletion Syndrome.

Authors:  Dina M Aresvik; Torstein Øverland; Kari Lima; Rolf D Pettersen; Tore G Abrahamsen
Journal:  J Clin Immunol       Date:  2018-12-19       Impact factor: 8.317

4.  Significance of Fas and Fas ligand in tuberculous lymphadenitis.

Authors:  Tehmina Mustafa; Stanley J Mogga; Sayoki G M Mfinanga; Odd Mørkve; Lisbet Sviland
Journal:  Immunology       Date:  2005-02       Impact factor: 7.397

5.  Fas (CD95) induces alveolar epithelial cell apoptosis in vivo: implications for acute pulmonary inflammation.

Authors:  G Matute-Bello; R K Winn; M Jonas; E Y Chi; T R Martin; W C Liles
Journal:  Am J Pathol       Date:  2001-01       Impact factor: 4.307

6.  Fas counterattack in cholangiocarcinoma: a mechanism for immune evasion in human hilar cholangiocarcinomas.

Authors:  Z Y Li; S Q Zou
Journal:  World J Gastroenterol       Date:  2001-12       Impact factor: 5.742

7.  Soluble FAS ligand as a biomarker of disease recurrence in differentiated thyroid cancer.

Authors:  Taofeek K Owonikoko; Mohammad S Hossain; Chandar Bhimani; Zhengjia Chen; Sungjin Kim; Suresh S Ramalingam; Shi-Yong Sun; Dong M Shin; Edmund K Waller; Fadlo R Khuri
Journal:  Cancer       Date:  2013-01-22       Impact factor: 6.860

8.  Gammadelta T cells promote a Th1 response during coxsackievirus B3 infection in vivo: role of Fas and Fas ligand.

Authors:  Sally Huber; Cuixia Shi; Ralph C Budd
Journal:  J Virol       Date:  2002-07       Impact factor: 5.103

9.  Prevalence of acute kidney injury and prognostic significance in patients with acute myocarditis.

Authors:  Ya-Wen Yang; Che-Hsiung Wu; Wen-Je Ko; Vin-Cent Wu; Jin-Shing Chen; Nai-Kuan Chou; Hong-Shiee Lai
Journal:  PLoS One       Date:  2012-10-29       Impact factor: 3.240

10.  Soluble Fas ligand released by colon adenocarcinoma cells induces host lymphocyte apoptosis: an active mode of immune evasion in colon cancer.

Authors:  E Song; J Chen; N Ouyang; F Su; M Wang; U Heemann
Journal:  Br J Cancer       Date:  2001-09-28       Impact factor: 7.640
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.